Drug intelligence / Profile preview

cephalosporin C

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01

Overview

Cephalosporin C is a naturally occurring beta-lactam antibiotic of the cephalosporin class, originally isolated from the fungus Acremonium chrysogenum. It was first characterized in 1961 and served as the lead compound for the development of many synthetic cephalosporins, such as cefalotin. Cephalosporin C itself has weak antibacterial activity and was never commercialized as a therapeutic drug. Its mechanism of action involves inhibition of penicillin binding proteins (PBPs), which are enzymes essential for bacterial cell wall synthesis, leading to bactericidal effects. Cephalosporins are generally used to treat various bacterial infections, especially in patients allergic to penicillins[6][9][1].

Other names
7-(5-amino-5-carboxyvaleramido)cephalosporanic acidCHEBI:157763XIY7HJT5L
02

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on cephalosporin C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cephalosporin C.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call